Meeting
2014 ASCO Annual Meeting
Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.
Authors
Geoffrey R. Oxnard
Dana-Farber Cancer Institute, Boston, MA
Geoffrey R. Oxnard , Christine A. Lydon , Neal Ian Lindeman , Priyanka R. Shivdasani , Gary Y. Chin , Frank C. Kuo , Bruce E. Johnson , Pasi A. Janne , Lynette M. Sholl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8090)
DOI
10.1200/jco.2014.32.15_suppl.8090
Abstract #
8090
Poster Bd #
271
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Upfront next generation sequencing in NSCLC: A publicly funded perspective.
First Author: Kirstin Perdrizet
Poster
2014 ASCO Annual Meeting
Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history.
First Author: Alexander E. Drilon
Poster
2013 ASCO Annual Meeting
Multiplexed genetic analysis of malignant pleural mesothelioma and the relationship to clinical outcome.
First Author: Takehito Shukuya
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates